Get the Stockscreener App
0.903
5.40%
0.0463
After Hours:
.89
-0.013
-1.44%
Lexaria Bioscience Corp stock is traded at $0.903, with a volume of 257.11K.
It is up +5.40% in the last 24 hours and down -24.12% over the past month.
Lexaria Bioscience Corp's patented drug delivery technology, DehydraTECH improves the way active pharmaceutical ingredients enter the bloodstream by promoting more effective oral delivery. DehydraTECH can increase bio-absorption with cannabinoids and nicotine by 5-10x and, in some instances with cannabinoids by as much as 27x compared to standard industry formulations, reduce the time of onset from 1-2 hours to minutes, and mask unwanted tastes. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood-brain barrier. The company has four reportable segments: Intellectual Property Licensing which generates maximum revenue, B2B Production, Research and Development, and Corporate. Geographically, it derives revenue from the United States and Canada.
See More
Previous Close:
$0.8567
Open:
$0.83
24h Volume:
257.11K
Relative Volume:
0.60
Market Cap:
$17.66M
Revenue:
$411.00K
Net Income/Loss:
$-4.85M
P/E Ratio:
-2.0523
EPS:
-0.44
Net Cash Flow:
$-4.88M
1W Performance:
+7.50%
1M Performance:
-24.12%
6M Performance:
-33.11%
1Y Performance:
-70.87%
1-Day Range:
$0.83
$0.9246
1-Week Range:
$0.8019
$0.99
52-Week Range:
$0.7749
$3.15
Lexaria Bioscience Corp Stock (LEXX) Company Profile
Name
Lexaria Bioscience Corp
Sector
Industry
Phone
250-765-6424
Address
100 - 740 MCCURDY ROAD, KELOWNA
Compare LEXX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LEXX
Lexaria Bioscience Corp
|
0.903 | 19.04M | 411.00K | -4.85M | -4.88M | -0.44 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.37 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.95 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
557.73 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
799.56 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
327.03 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Lexaria Bioscience Corp Stock (LEXX) Latest News
What catalysts could drive Lexaria Bioscience Corp. stock higherShort Setup & Real-Time Chart Breakout Alerts - newser.com
Price action breakdown for Lexaria Bioscience Corp. Equity WarrantCEO Change & Daily Stock Trend Reports - newser.com
Combining machine learning predictions for Lexaria Bioscience Corp. Equity WarrantJuly 2025 WrapUp & Expert Curated Trade Setup Alerts - newser.com
Can trapped investors hope for a rebound in Lexaria Bioscience Corp. Equity WarrantPortfolio Risk Summary & Free Growth Oriented Trading Recommendations - newser.com
How Lexaria Bioscience Corp. stock performs in rising dollar environmentJuly 2025 Earnings & Reliable Entry Point Alerts - newser.com
Is Lexaria Bioscience Corp. Equity Warrant stock in correction or buying zone2025 Pullback Review & AI Forecasted Entry/Exit Points - newser.com
Is Lexaria Bioscience Corp. stock ready for a breakoutAnalyst Upgrade & Low Drawdown Investment Strategies - newser.com
Will Lexaria Bioscience Corp. Equity Warrant outperform the marketTrade Risk Summary & Technical Buy Zone Confirmations - newser.com
Earnings visualization tools for Lexaria Bioscience Corp. Equity Warrant2025 Valuation Update & Safe Capital Growth Tips - newser.com
Can Lexaria Bioscience Corp. hit a new high this monthMarket Risk Analysis & Smart Allocation Stock Reports - newser.com
Lexaria expands pharmaceutical outreach with new advisory firm By Investing.com - Investing.com Nigeria
Lexaria Bioscience Corp. Provides Strategic Update - NewMediaWire
Lexaria Bioscience Expands Strategic Outreach and Secures New Patents - TipRanks
Lexaria (LEXX) Expands R&D Efforts with Enhanced Funding and New Partnerships - GuruFocus
Lexaria expands pharmaceutical outreach with new advisory firm - Investing.com India
$4.0M Financing backs Lexaria's global BD push; 4 new patents bolster DehydraTECH R&D into 2026 - Stock Titan
Can trapped investors hope for a rebound in Lexaria Bioscience Corp.2025 Major Catalysts & Community Verified Swing Trade Signals - newser.com
Historical volatility pattern of Lexaria Bioscience Corp. visualized2025 Institutional Moves & Fast Momentum Stock Entry Tips - newser.com
Custom watchlist performance reports with Lexaria Bioscience Corp.2025 Major Catalysts & Pattern Based Trade Signal System - newser.com
News impact scoring models applied to Lexaria Bioscience Corp. Equity WarrantMarket Sentiment Report & Real-Time Volume Analysis - newser.com
Can swing trading help recover from Lexaria Bioscience Corp. Equity Warrant losses2025 Key Lessons & Weekly Top Gainers Alerts - newser.com
Lexaria Bioscience Corp Stock Analysis and ForecastAutomated Trading Signals & Explosive Capital Growth - earlytimes.in
Will Lexaria Bioscience Corp. see short term momentumMarket Sentiment Report & Fast Entry High Yield Stock Tips - newser.com
Lexaria Bioscience Corp. Equity Warrant stock daily chart insightsWeekly Risk Report & High Conviction Trade Alerts - newser.com
Real time social sentiment graph for Lexaria Bioscience Corp.Quarterly Trade Review & Technical Pattern Based Buy Signals - newser.com
Smart tools for monitoring Lexaria Bioscience Corp.’s price actionWeekly Market Outlook & Weekly Stock Performance Updates - newser.com
Can Lexaria Bioscience Corp. Equity Warrant stock deliver surprise earnings beatCPI Data & Fast Moving Trade Plans - newser.com
When is the best time to exit Lexaria Bioscience Corp.Entry Point & Community Verified Trade Signals - newser.com
Is Lexaria Bioscience Corp. stock reversal real or fakeAnalyst Downgrade & Reliable Price Action Trade Plans - newser.com
What drives Lexaria Bioscience Corp stock priceFundamental Stock Analysis & High Yield Trading Plans - earlytimes.in
Lexaria Bioscience Corp. Equity Warrant stock trendline breakdownWeekly Stock Summary & Accurate Buy Signal Alerts - newser.com
What’s next for Lexaria Bioscience Corp. Equity Warrant stock price2025 Price Action Summary & Breakout Confirmation Alerts - newser.com
Chart based exit strategy for Lexaria Bioscience Corp. Equity WarrantJuly 2025 Momentum & Free High Return Stock Watch Alerts - newser.com
Will earnings trigger a reversal in Lexaria Bioscience Corp.2025 Stock Rankings & Reliable Trade Execution Plans - newser.com
LEXX: Biodistribution Study Results - Yahoo Finance
Lexaria Bioscience announces ~$4M registered direct offering of shares - MSN
Lexaria Bioscience Corp Stock (LEXX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Lexaria Bioscience Corp Stock (LEXX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| BUNKA CHRISTOPHER | Director |
Jul 30 '25 |
Buy |
0.91 |
11,900 |
10,866 |
281,912 |
| McKechnie William Edward | Director |
Jul 29 '25 |
Buy |
0.91 |
5,000 |
4,532 |
18,191 |
| DOCHERTY JOHN MARTIN | President & CSO |
Jul 29 '25 |
Buy |
0.93 |
5,376 |
4,989 |
5,376 |
| Carle Vanessa | Secretary |
Jul 29 '25 |
Buy |
0.91 |
750 |
682 |
750 |
| CHRISTOPHER RICHARD | Chief Executive Officer |
Jul 29 '25 |
Buy |
0.91 |
15,000 |
13,641 |
65,000 |
| CHRISTOPHER RICHARD | Chief Executive Officer |
Dec 03 '24 |
Buy |
2.47 |
27,172 |
67,175 |
50,000 |
| CHRISTOPHER RICHARD | Chief Executive Officer |
Dec 02 '24 |
Buy |
2.24 |
22,828 |
51,217 |
22,828 |
1.11%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):